Description
Clinical Description
Plenhyage XL Strong is a Class III CE-marked injectable medical device produced by Bioformula s.r.l. (Italy), formulated with 2.5% high-molecular-weight polynucleotides (PDRN) derived from salmon DNA. The mechanism centres on fibroblast activation, extracellular-matrix regeneration and enhanced dermal hydration via polynucleotide-mediated tissue renewal. The formulation is designed for treating more advanced signs of skin aging, photo-damage or fibrotic tissue changes, rather than volumetric augmentation. Suggested indications include skin laxity, loss of elasticity, fine lines and sun-damaged skin over face, neck, décolletage and body regions.
What Plenhyage XL Strong Is Similar To
Plenhyage XL Strong falls within the higher-concentration polynucleotide (PN) biostimulator category and can be compared with products like Jalupro Advanced (which combines amino acids + PDRN) and other PN-based skin boosters. While Jalupro offers a combined amino-acid/PDRN modality targeting moderate skin degradation, Plenhyage XL Strong provides a higher single-active PDRN concentration (2.5%) for more intensive regenerative support. Compared to its sister formulations — Plenhyage XL Medium (~2.0%) and Plenhyage XL Thin (~0.75%) — the Strong variant is suited to more pronounced skin aging or body applications. For orientation, the HA-based bioremodeller Profhilo targets skin quality improvement via large-volume HA diffusion rather than PN-based cellular activation; thus choice depends on mechanism and indication.
This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
According to manufacturer product page:
-
Face (including moderate-to-advanced signs of aging)
-
Neck and décolletage
-
Body zones (hands, inner arms, thighs, knees) in cases of skin laxity/fibrosis
Usage / Administration (IFU-only section)
-
Injection depth: not provided by manufacturer in publicly-accessible product page.
-
Volume per point / injection site: not provided by manufacturer.
-
Needle gauge: not provided by manufacturer.
-
Frequency / number of sessions: Manufacturer states: “duration of the treatment varies depending on individual needs and the area treated. Multiple sessions are usually required.”
-
Professional-use disclaimer: “Class III medical device intended for professional medical use only.”
Note: Some practitioners apply a protocol of 2-4 sessions at 2-4-week intervals followed by maintenance every 6-12 months — this is not part of the official manufacturer IFU (has been reported by distributors).
Ingredient List
-
Polynucleotides (PDRN) — 2.5% high-molecular-weight (approx. 25 mg/ml) in Strong variant.
-
Sterile water, buffering agents and other excipients — specific excipient list not provided by manufacturer in public domain.
-
Lidocaine: not provided by manufacturer (product page does not list anaesthetic).
-
Hyaluronic acid: Some distributor pages mention HA inclusion, but manufacturer site focuses on PN only; exact HA concentration for this variant is not verified in public documentation.
Presentation & Longevity
-
Presentation: 1 × 2 ml pre-filled glass syringe with 2 disposable needles.
-
Shelf-life/storage: not publicly specified on product page; verify via IFU and packaging.
-
Duration of effect: Manufacturer notes that treatment duration varies depending on individual needs and area treated. Distributor references suggest effects lasting 6–12 months in many cases (depending on skin condition and maintenance) but this is not officially guaranteed.
Safety Notes / Contraindications
-
Use is contraindicated in patients with known hypersensitivity to any component.
-
Do not inject into or adjacent to sites with active skin infection, inflammation or open wounds.
-
Use only by trained medical professionals under sterile conditions. Improper use may increase adverse-event risk.
-
For details on other contraindications (e.g., pregnancy/breastfeeding, immunocompromised states, autoimmune disorders) refer to full IFU and local regulations — public documentation is limited.
Regulatory Status
-
CE-marked: Class III medical device, CE 0373.
-
UKCA / FDA clearance: not explicitly stated in publicly accessible manufacturer page — verify on product pack or distributor documentation before use in UK/other markets.
FAQ
Q1: How exactly does Plenhyage XL Strong work?
A1: The product uses high-molecular-weight polynucleotides (PDRN) which act as bio-regenerative molecules. They stimulate fibroblasts, enhance extracellular-matrix repair and increase dermal hydration via binding water molecules. This supports improved skin elasticity and structure rather than immediate volumetric fill .
Q2: Is Plenhyage XL Strong safe to use?
A2: According to manufacturer data, the device is well-tolerated when administered by a qualified medical professional. Mild transient reactions (e.g., swelling, redness, bruising) are possible. Strict adherence to professional use, aseptic technique and proper patient selection minimise risks .
Q3: How often should the treatment be performed?
A3: The manufacturer indicates that multiple sessions are usually required and that treatment plans should be personalised. Specific injection intervals or counts are not given in the IFU [1]. Some practitioner protocols – not official – suggest 2–4 sessions with 2–4-week intervals, followed by maintenance every 6–12 months .
Q4: How long will the results last?
A4: Manufacturer guidance states that results vary depending on patient factors and treatment area. While distributor practice data report 6–12 months duration for many cases, this is not a guaranteed timeframe and should be discussed with the clinician.
Q5: Can Plenhyage XL Strong be used instead of a hyaluronic-acid filler?
A5: Not as a direct replacement: Plenhyage XL Strong is a polynucleotide-based biostimulator targeting tissue regeneration and skin quality improvement, whereas HA fillers primarily provide volume and structural support. Treatment choice should align with the clinical objective — regeneration vs volumisation .
